Evidence map›Paper›PMID 30371253›Full record

ArticleJournal of the American Heart Association2018

Liver Disease as a Predictor of New-Onset Atrial Fibrillation.

William A Huang, Eric A Dunipace, Julie M Sorg, Marmar Vaseghi

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Double Trouble: The Challenge of Neuroprotection in Patients with Liver Cirrhosis and Atrial Fibrillation.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Article
  15. Review
  16. Cardiac Syndromes in Liver Disease: A Clinical Conundrum.Journal of clinical and translational hepatology · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

William A Huang1 UCLA Cardiac Arrhythmia Center David Geffen School of Medicine at UCLA University of California Los Angeles CA.
Eric A Dunipace1 UCLA Cardiac Arrhythmia Center David Geffen School of Medicine at UCLA University of California Los Angeles CA.
Julie M Sorg1 UCLA Cardiac Arrhythmia Center David Geffen School of Medicine at UCLA University of California Los Angeles CA.
Marmar Vaseghi1 UCLA Cardiac Arrhythmia Center David Geffen School of Medicine at UCLA University of California Los Angeles CA.
University of California, Los Angeles · USHarvard University · US

Funding

GRADUATE TRAINING IN BIOSTATISTICST32ES007142 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Brent Andrew Coull · 1985 to 2026
$11.9M
Cardiac Afferent Neurotransmission and Modulation of Ventricular Parasympathetic ControlDP2HL132356 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VASEGHI, MARMAR · 2015 to 2015
$2.3M
NHLBI NIH HHS DP2 HL132356NIEHS NIH HHS T32 ES007142
6 · The paper itself

Abstract

Background Impact of liver disease on development of atrial fibrillation ( AF ) is unclear. The purpose of the study was to evaluate prevalence of AF in the setting of liver disease and whether increasing severity of liver disease, using Model for End-Stage Liver Disease ( MELD ), is independently associated with increased risk of AF . Methods and Results Retrospective data analysis of 1727 patients with liver disease evaluated for liver transplantation between 2006 and 2015 was performed, and patient characteristics were analyzed from billing codes and review of medical records. Multivariable time-dependent Cox proportional hazards model was performed to determine effect of increasing MELD score on risk of developing AF . Prevalence of AF was 11.2%. Incidence of AF at median follow-up time of 1.04 years was 8.5%. Both prevalence and incidence of AF increased with increasing MELD scores. Prevalence of AF was 3.7%, 6.4%, 16.7%, and 20.2% corresponding with MELD quartiles 1 to 10, 11 to 20, 21 to 30, and >30, respectively. Compared with patients with MELD quartile 1 to 10, patients with MELD quartile of 11 to 20 had hazard ratio of 2.73 (confidence interval, 1.47-5.07), those in the MELD quartile of 21 to 30 had a hazard ratio of 5.17 (confidence interval, 2.65-10.09), and those with MELD values >30 had hazard ratio of 9.33 (confidence interval, 3.93-22.14) for development of new-onset AF . Other significant variables associated with new-onset AF were age, sleep apnea, valvular heart disease, hemodynamic instability, and reduced left ventricular ejection fraction <50% (hazard ratio, of 1.06, 2.17, 3.21, 2.00, and 2.44, respectively). Conclusions Prevalence and incidence of AF in patients with liver disease is high. Severity of liver disease, as measured by MELD , is an important predictor of new-onset AF . This novel finding suggests an interaction between inflammatory and neurohormonal changes in liver disease and pathogenesis of AF .

Indexed as

AdultAgedAge FactorsAtrial FibrillationCarcinoma, HepatocellularEnd Stage Liver DiseaseFemaleHeart Valve DiseasesHepatitis CHumansIncidenceLiver DiseasesLiver Diseases, AlcoholicLiver NeoplasmsMaleMiddle Agedatrial fibrillationatrial fibrillation arrhythmiacirrhosisliver diseaseModel for End‐Stage Liver Disease

Identifiers

PMID30371253
PMCPMC6201455
OpenAlexW2884924206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.